Synthetic cathinones: "A khat and mouse game"

Toxicology Letters

Volumn 229, Issue 2, 2014, Pages 349-356

  Katz, Daniel P ^a   Bhattacharya, Dwipayan ^a   Bhattacharya, Subhrajit ^a   Deruiter, Jack ^a   Clark, C Randall ^a   Suppiramaniam, Vishnu ^a   Dhanasekaran, Muralikrishnan ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

Addiction; Bath salts; Designer drug; MDPV; Stimulant; Synthetic cathinone

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; CATHINONE; COCAINE;

ARTICLE; BLOOD BRAIN BARRIER; CATHA EDULIS; CHEMISTRY; DRUG ABUSE; DRUG COMBINATION; DRUG DETERMINATION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; LAW ENFORCEMENT; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; NEUROTRANSMITTER RELEASE; NONHUMAN; PHARMACOKINETICS; PHARMACOLOGY; PRIORITY JOURNAL;

ADDICTION; BATH SALTS; DESIGNER DRUG; MDPV; STIMULANT; SYNTHETIC CATHINONE;

ALKALOIDS; ANIMALS; CATHA; CENTRAL NERVOUS SYSTEM STIMULANTS; DESIGNER DRUGS; HUMANS; SUBSTANCE-RELATED DISORDERS;

EID: 84904332902     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2014.06.020     Document Type: Review

References (78)

1. Aarde S.M., Huang P.K., Creehan K.M., Dickerson T.J., Taffe M.A. The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: self-administration and locomotor activity in rats. Neuropharmacology 2013, 71:130-140. Research Support, N.I.H., Extramural. 10.1016/j.neuropharm.2013.04.003.
2. Al-Obaid A.M., al-Tamrah S.A., Aly F.A., Alwarthan A.A. Determination of (S)(-)-cathinone by spectrophotometric detection. J. Pharm. Biomed. Anal. 1998, 17(2):321-326.
3. Angoa-Perez M., Kane M.J., Francescutti D.M., Sykes K.E., Shah M.M., Mohammed A.M., Kuhn D.M. Mephedrone, an abused psychoactive component of 'bath salts' and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum. J. Neurochem. 2012, 120(6):1097-1107. Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S. 10.1111/j.1471-4159.2011.07632.
4. Bauer C.T., Banks M.L., Blough B.E., Negus S.S. Use of intracranial self-stimulation to evaluate abuse-related and abuse-limiting effects of monoamine releasers in rats. Br. J. Pharmacol. 2013, 168(4):850-862. Research Support, N.I.H., Extramural. 10.1111/j.1476-5381.2012.02214.x.
5. Baumann M.H., Ayestas M.A., Partilla J.S., Sink J.R., Shulgin A.T., Daley P.F., Cozzi N.V. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 2012, 37(5):1192-1203. In Vitro Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't. 10.1038/npp.2011.304.
6. Baumann M.H., Partilla J.S., Lehner K.R. Psychoactive "bath salts": not so soothing. Eur. J. Pharmacol. 2013, 698(1-3):1-5. Research Support, N.I.H., Intramural Review. 10.1016/j.ejphar.2012.11.020.
7. Baumann M.H., Partilla J.S., Lehner K.R., Thorndike E.B., Hoffman A.F., Holy M., Schindler C.W. Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products. Neuropsychopharmacology 2013, 38(4):552-562. Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't. 10.1038/npp.2012.204.
8. Borek H.A., Holstege C.P. Hyperthermia and multiorgan failure after abuse of "bath salts" containing 3,4-methylenedioxypyrovalerone. Ann. Emerg. Med. 2012, 60(1):103-105. Case Reports. 10.1016/j.annemergmed.2012.01.005.
9. Brandt S.D., Sumnall H.R., Measham F., Cole J. Analyses of second-generation 'legal highs' in the UK: initial findings. Drug Test. Anal. 2010, 2(8):377-382. 10.1002/dta.155.
10. Brock, T.G., 2013. Structural similarities of amphetamine and methamphetamine with their β-keto equivalents. Cathinones- Illicit Drugs.
11. Brunt T.M., Poortman A., Niesink R.J., van den Brink W. Instability of the ecstasy market and a new kid on the block: mephedrone. J. Psychopharmacol. 2011, 25(11):1543-1547. Research Support, Non-U.S. Gov't. 10.1177/0269881110378370.
12. Calabrese E.J. Addiction and dose response: the psychomotor stimulant theory of addiction reveals that hormetic dose responses are dominant. Crit. Rev. Toxicol. 2008, 38(7):599-617. 10.1080/10408440802026315.
13. Coppola M., Mondola R. Synthetic cathinones: chemistry, pharmacology and toxicology of a new class of designer drugs of abuse marketed as "bath salts" or "plant food". Toxicol. Lett. 2012, 211(2):144-149. Review. 10.1016/j.toxlet.2012.03.009.
14. Cozzi N.V., Sievert M.K., Shulgin A.T., Jacob P., Ruoho A.E. Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines. Eur. J. Pharmacol. 1999, 381(1):63-69. Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.
15. Dal Cason T.A., Young R., Glennon R.A. Cathinone: an investigation of several N-alkyl and methylenedioxy-substituted analogs. Pharmacol. Biochem. Behav. 1997, 58(4):1109-1116. Research Support, U.S. Gov't, P.H.S.
16. Deluca, P.S.F., Davey, Z., Corazza, O., Di Furia, L., and the psychonaut web mapping research group, 2009. Mephedrone report.
17. Den Hollander B., Rozov S., Linden A.M., Uusi-Oukari M., Ojanpera I., Korpi E.R. Long-term cognitive and neurochemical effects of "bath salt" designer drugs methylone and mephedrone. Pharmacol. Biochem. Behav. 2013, 103(3):501-509. Research Support, Non-U.S. Gov't. 10.1016/j.pbb.2012.10.006.
18. Durham M. Ivory wave: the next mephedrone?. Emerg. Med. J. 2011, 28(12):1059-1060. Case Reports Review. 10.1136/emj.2011.112920.
19. Fantegrossi W.E., Gannon B.M., Zimmerman S.M., Rice K.C. In vivo effects of abused 'bath salt' constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, thermoregulation, and locomotor activity. Neuropsychopharmacology 2013, 38(4):563-573. Research Support, N.I.H., Extramural. 10.1038/npp.2012.233.
20. Feyissa A.M., Kelly J.P. A review of the neuropharmacological properties of khat. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32(5):1147-1166. Research Support, Non-U.S. Gov't Review. 10.1016/j.pnpbp.2007.12.033.
21. Gibbons S., Zloh M. An analysis of the 'legal high' mephedrone. Bioorg. Med. Chem. Lett. 2010, 20(14):4135-4139. 10.1016/j.bmcl.2010.05.065.
22. Gygi M.P., Gibb J.W., Hanson G.R. Methcathinone: an initial study of its effects on monoaminergic systems. J. Pharmacol. Exp. Ther. 1996, 276(3):1066-1072. Research Support, U.S. Gov't, P.H.S.
23. Gygi M.P., Fleckenstein A.E., Gibb J.W., Hanson G.R. Role of endogenous dopamine in the neurochemical deficits induced by methcathinone. J. Pharmacol. Exp. Ther. 1997, 283(3):1350-1355. Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.
24. Hadlock G.C., Webb K.M., McFadden L.M., Chu P.W., Ellis J.D., Allen S.C., Fleckenstein A.E. 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J. Pharmacol. Exp. Ther. 2011, 339(2):530-536. Research Support, N.I.H., Extramural. 10.1124/jpet.111.184119.
25. Hand, T.R.A., 2009. Seizures of drugs in England and Wales.
26. Hanson, D., 2012. Chemical structures of synthetic cathinones derived from methcathinone. Catching up with bath salts and spice. In: 08/01/2012.
27. Hill S.L., Thomas S.H.L. Clinical toxicology of newer recreational drugs. Clin. Toxicol. 2011, 49(8):705-719. 10.3109/15563650.2011.615318.
28. Huang P.K., Aarde S.M., Angrish D., Houseknecht K.L., Dickerson T.J., Taffe M.A. Contrasting effects of d-methamphetamine, 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxypyrovalerone, and 4-methylmethcathinone on wheel activity in rats. Drug Alcohol Depend. 2012, 126(1-2):168-175. Comparative Study Research Support, N.I.H., Extramural. 10.1016/j.drugalcdep.2012.05.011.
29. Karila L., Reynaud M. GHB and synthetic cathinones: clinical effects and potential consequences. Drug Test. Anal. 2011, 3(9):552-559. Review. 10.1002/dta.210.
30. Karuppagounder S.S., Bhattacharya D., Ahuja M., Suppiramaniam V., Deruiter J., Clark R., Dhanasekaran M. Elucidating the neurotoxic effects of MDMA and its analogs. Life Sci. 2014, 101:37-42.
31. Kasick D.P., McKnight C.A., Klisovic E. "Bath salt" ingestion leading to severe intoxication delirium: two cases and a brief review of the emergence of mephedrone use. Am. J. Drug Alcohol Abuse 2012, 38(2):176-180. Case Reports. 10.3109/00952990.2011.643999.
32. Kehr J., Ichinose F., Yoshitake S., Goiny M., Sievertsson T., Nyberg F., Yoshitake T. Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Br. J. Pharmacol. 2011, 164(8):1949-1958. Research Support, Non-U.S. Gov't. 10.1111/j.1476-5381.2011.01499.x.
33. Kikura-Hanajiri R., Kawamura M., Saisho K., Kodama Y., Goda Y. The disposition into hair of new designer drugs; methylone, MBDB and methcathinone. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 855(2):121-126. Comparative Study Research Support, Non-U.S. Gov't. 10.1016/j.jchromb.2007.05.018.
34. Krikorian A.D. Kat and its use: an historical perspective. J. Ethnopharmacol. 1984, 12(2):115-178. Historical Article Research Support, Non-U.S. Gov't.
35. Macher A.M., Penders T.M. False-positive phencyclidine immunoassay results caused by 3,4-methylenedioxypyrovalerone (MDPV). Drug Test. Anal. 2013, 5(2):130-132. Comment Letter. 10.1002/dta.1371.
36. Marks R.C., Luchins D.J. Antipsychotic medications and seizures. Psychiatr. Med. 1991, 9(1):37-52. Review.
37. Mash D.C., Duque L., Pablo J., Qin Y., Adi N., Hearn W.L., Wetli C.V. Brain biomarkers for identifying excited delirium as a cause of sudden death. Forensic Sci. Int. 2009, 190(1-3):e13-e19. Research Support, N.I.H., Extramural. 10.1016/j.forsciint.2009.05.012.
38. Meyer M.R., Du P., Schuster F., Maurer H.H. Studies on the metabolism of the alpha-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS. J. Mass Spectrom. 2010, 45(12):1426-1442. Research Support, Non-U.S. Gov't. 10.1002/jms.1859.
39. Meyer M.R., Wilhelm J., Peters F.T., Maurer H.H. Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal. Bioanal. Chem. 2010, 397(3):1225-1233. 10.1007/s00216-010-3636-5.
40. Miller G.M. The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. J. Neurochem. 2011, 116(2):164-176. Research Support, N.I.H., Extramural Review. 10.1111/j.1471-4159.2010.07109.x.
41. Miller M.L., Creehan K.M., Angrish D., Barlow D.J., Houseknecht K.L., Dickerson T.J., Taffe M.A. Changes in ambient temperature differentially alter the thermoregulatory, cardiac and locomotor stimulant effects of 4-methylmethcathinone (mephedrone). [Research Support, N. I. H., Extramural]. Drug Alcohol Depend. 2013, 127(1-3):248-253. Research Support, N.I.H., Extramural. 10.1016/j.drugalcdep.2012.07.003.
42. Motbey C.P., Karanges E., Li K.M., Wilkinson S., Winstock A.R., Ramsay J., Gregor Mc, I.S Mephedrone in adolescent rats: residual memory impairment and acute but not lasting 5-HT depletion. PLoS One 2012, 7(9):e45473. Research Support, Non-U.S. Gov't. 10.1371/journal.pone.0045473.
43. Murray B.L., Murphy C.M., Beuhler M.C. Death following recreational use of designer drug "bath salts" containing 3,4-Methylenedioxypyrovalerone (MDPV). J. Med. Toxicol. 2012, 8(1):69-75. Case Reports. 10.1007/s13181-011-0196-9.
44. Newcombe, 2009. Mephedrone: use of mephedrone (M-Cat Meow) in Middlesbrough.
45. Penders T.M., Gestring R. Hallucinatory delirium following use of MDPV: "bath salts". Gen. Hosp. Psychiatry 2011, 33(5):525-526. Case Reports. 10.1016/j.genhosppsych.2011.05.014.
46. Prosser J.M., Nelson L.S. The toxicology of bath salts: a review of synthetic cathinones. J. Med. Toxicol. 2012, 8(1):33-42. Review. 10.1007/s13181-011-0193-z.
47. Regan L., Mitchelson M., Macdonald C. Mephedrone toxicity in a Scottish emergency department. Emerg. Med. J. 2011, 28(12):1055-1058. Review. 10.1136/emj.2010.103093.
48. Rosenbaum C.D., Carreiro S.P., Babu K.M. Here today, gone tomorrow and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. J. Med. Toxicol. 2012, 8(1):15-32. Review. 10.1007/s13181-011-0202-2.
49. Ross E.A., Reisfield G.M., Watson M.C., Chronister C.W., Goldberger B.A. Psychoactive "bath salts" intoxication with methylenedioxypyrovalerone. Am. J. Med. 2012, 125(9):854-858. Review. 10.1016/j.amjmed.2012.02.019.
50. Rudnick G., Wall S.C. Non-neurotoxic amphetamine derivatives release serotonin through serotonin transporters. Mol. Pharmacol. 1993, 43(2):271-276. In Vitro Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.
51. Ruttenber A.J., Lawler-Heavner J., Yin M., Wetli C.V., Hearn W.L., Mash D.C. Fatal excited delirium following cocaine use: epidemiologic findings provide new evidence for mechanisms of cocaine toxicity. J. Forensic Sci. 1997, 42(1):25-31. Research Support, U.S. Gov't, P.H.S.
52. Sawair F.A., Al-Mutwakel A., Al-Eryani K., Al-Surhy A., Maruyama S., Cheng J., Saku T. High relative frequency of oral squamous cell carcinoma in Yemen: qat and tobacco chewing as its aetiological background. Int. J. Environ. Health Res. 2007, 17(3):185-195. Research Support, Non-U.S. Gov't. 10.1080/09603120701254813.
53. Scottdouglas, J., 2013. Fresh leaves and shoots of the khat plant, Catha edulis Forsk Yemen- country of khat. http://www.suncoastrehabcenter.com/wp-content/uploads/2013/08/khat.jpg.
54. Shanks K.G., Dahn T., Behonick G., Terrell A. Analysis of first and second generation legal highs for synthetic cannabinoids and synthetic stimulants by ultra-performance liquid chromatography and time of flight mass spectrometry. J. Anal. Toxicol. 2012, 36(6):360-371. 10.1093/jat/bks047.
55. Shortall S.E., Macerola A.E., Swaby R.T., Jayson R., Korsah C., Pillidge K.E., King M.V. Behavioural and neurochemical comparison of chronic intermittent cathinone, mephedrone and MDMA administration to the rat. Eur. Neuropsychopharmacol. 2013, 23(9):1085-1095. Research Support, Non-U.S. Gov't. 10.1016/j.euroneuro.2012.09.005.
56. Show, T.D.O., 2011. Alternative product names for "bath salts". Alternate names for the "bath salt" drug [Online]. http://www.doctoroz.com/videos/alternate-names-bath-salt-drug.
57. Simmler L.D., Buser T.A., Donzelli M., Schramm Y., Dieu L.H., Huwyler J., Liechti M.E. Pharmacological characterization of designer cathinones in vitro. Br. J. Pharmacol. 2013, 168(2):458-470. Research Support, Non-U.S. Gov't. 10.1111/j.1476-5381.2012.02145.x.
58. Sparago M., Wlos J., Yuan J., Hatzidimitriou G., Tolliver J., Dal Cason T.A., Ricaurte G. Neurotoxic and pharmacologic studies on enantiomers of the N-methylated analog of cathinone (methcathinone): a new drug of abuse. J. Pharmacol. Exp. Ther. 1996, 279(2):1043-1052. Research Support, U.S. Gov't, P.H.S.
59. Spiller H.A., Ryan M.L., Weston R.G., Jansen J. Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States. Clin. Toxicol. (Phila) 2011, 49(6):499-505. 10.3109/15563650.2011.590812.
60. Strano-Rossi S., Cadwallader A.B., de la Torre X., Botre F. Toxicological determination and in vitro metabolism of the designer drug methylenedioxypyrovalerone (MDPV) by gas chromatography/mass spectrometry and liquid chromatography/quadrupole time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 2010, 24(18):2706-2714. 10.1002/rcm.4692.
61. Sulzer D., Rayport S. Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action. Neuron 1990, 5(6):797-808. Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.
62. Takeuchi A., Ahern T.L., Henderson S.O. Excited delirium. West. J. Emerg. Med. 2011, 12(1):77-83.
63. Torrance H., Cooper G. The detection of mephedrone (4-methylmethcathinone) in 4 fatalities in Scotland. Forensic Sci. Int. 2010, 202(1-3):e62-e63. Letter. 10.1016/j.forsciint.2010.07.014.
64. Vardakou I., Pistos C., Spiliopoulou C. Drugs for youth via Internet and the example of mephedrone. Toxicol. Lett. 2011, 201(3):191-195. Case Reports Review. 10.1016/j.toxlet.2010.12.014.
65. Watterson L.R., Kufahl P.R., Nemirovsky N.E., Sewalia K., Grabenauer M., Thomas B.F., Olive M.F. Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV). Addict. Biol. 2012, 10.1111/j.1369-1600.2012.00474.x.
66. Winstock A., Mitcheson L., Marsden J. Mephedrone: still available and twice the price. Lancet 2010, 376(9752):1537. Letter. 10.1016/S0140-6736(10)62021-1.
67. Wise R.A., Bozarth M.A. A psychomotor stimulant theory of addiction. Psychol. Rev. 1987, 94(4):469-492. 10.1037/0033-295x.94.4.469.
68. Xie Z., Miller G.M. Trace amine-associated receptor 1 as a monoaminergic modulator in brain. Biochem. Pharmacol. 2009, 78(9):1095-1104. Research Support, N.I.H., Extramural. 10.1016/j.bcp.2009.05.031.
69. Yousef G., Huq Z., Lambert T. Khat chewing as a cause of psychosis. Br. J. Hosp. Med. 1995, 54(7):322-326. Case Reports.
70. Zaitsu K., Katagi M., Kamata H.T., Kamata T., Shima N., Miki A., Mori Y. Determination of the metabolites of the new designer drugs bk-MBDB and bk-MDEA in human urine. Forensic Sci. Int. 2009, 188(1-3):131-139. 10.1016/j.forsciint.2009.04.001.
71. http://www.aapcc.s3.amazonaws.com/files/library/Bath_Salts_Web_Data_through_12.2013_3 pdf (visited January 17, 2014).
72. http://www.bathsaltsdrug.blogspot.com/2011/04/americas-new-drug-problem-snorting-bath.html (visited April 25, 2014).
73. http://www.caymanchem.com/pdfs/10624 pdf (visited February 16, 2014).
74. http://www.drugs-forum.com (visited January 28, 2014).
75. http://www.emcdda.europa.eu/online/annual-report/2010/boxes/p92 (April 25, 2014).
76. http://www.erowid.org/experiences/subs/exp_MDPV.shtml (January 28, 2014).
77. http://www.justice.gov/dea/druginfo/ds.shtml (visited April 25, 2014).
78. http://www.samhsa.gov/data/spotlight/spot117-bath-salts-2013 pdf (visited April 25, 2014).